Myeloproliferative Neoplasms
Ruxolitinib outperformed best available therapies in achieving durable hematocrit control in patients with polycythemia vera.
Ruxolitinib plus navitoclax induced 24-week spleen volume reduction rates twice as high as ruxolitinib plus placebo in MF.
Pelabresib plus ruxolitinib induced significant spleen volume reduction rates without limiting toxicities in myelofibrosis.
Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis.
Meta-analysis findings support the use of statins in patients with PV and ET to reduce mortality and thrombosis risk.
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Advertisement
Expert Interviews on Hematology
Advertisement
